Future Fund LLC Sells 25,199 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Future Fund LLC trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 69.4% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 11,096 shares of the biopharmaceutical company’s stock after selling 25,199 shares during the period. Halozyme Therapeutics comprises 1.9% of Future Fund LLC’s investment portfolio, making the stock its 26th biggest position. Future Fund LLC’s holdings in Halozyme Therapeutics were worth $634,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of HALO. Congress Asset Management Co. grew its position in shares of Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after acquiring an additional 1,988,238 shares during the period. Handelsbanken Fonder AB lifted its stake in shares of Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after buying an additional 856,200 shares in the last quarter. TD Asset Management Inc lifted its stake in shares of Halozyme Therapeutics by 28.1% during the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after buying an additional 557,350 shares in the last quarter. Boston Trust Walden Corp purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at approximately $23,211,000. Finally, Swedbank AB purchased a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at approximately $13,927,000. 97.79% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total value of $592,000.00. Following the sale, the chief executive officer now owns 676,744 shares of the company’s stock, valued at $40,063,244.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 70,000 shares of company stock valued at $4,042,500 in the last quarter. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $59.61 on Wednesday. The firm has a market cap of $7.58 billion, a PE ratio of 19.74, a price-to-earnings-growth ratio of 0.56 and a beta of 1.29. Halozyme Therapeutics, Inc. has a 12-month low of $33.15 and a 12-month high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The company’s fifty day simple moving average is $56.53 and its two-hundred day simple moving average is $53.18.

Wall Street Analyst Weigh In

A number of analysts recently commented on HALO shares. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. The Goldman Sachs Group increased their target price on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research note on Monday, July 22nd. Benchmark reiterated a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. HC Wainwright increased their target price on shares of Halozyme Therapeutics from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price objective for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $61.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.